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were conducted in December 2002 in 15 Italian hospitals.
Three major topics were investigated, Hospital Formulary
(HF) listing process, epidemiology and medical need in
aHF, HF listing process for aHF drugs, a semi-structured
questionnaire was used and both spontaneous and
elicited citations were recorded. RESULTS: Most quoted
requisites were: superior efﬁcacy in comparison to avail-
able alternatives, better cost-effectiveness proﬁle, credi-
bility, and size of clinical studies. Innovation is relevant
to pharmacists, while QoL and length of hospital stay are
important mostly for cardiologists. Cardiologist and
pharmacists showed different level of information regard-
ing aHF. Similar average yearly number of aHF hospital-
isation were reported by both targets (cardiologists =
968,7 range 1–1000; pharmacists = 937,5 range 250–
1500) but response rate was only 27% among pharma-
cists. Eighty-seven percent of the pharmacists were unable
to rate aHF mortality in their hospitals, estimated by 
cardiologists from 6–7% to 60–70%. Cardiologists
scored clinical efﬁcacy (93%) and absence of contra-
indication/interactions (60%) as the most important char-
acteristics of aHF products, while innovation and clinical
documentation size and credibility (40% and 47%
respectively) are important to pharmacists. Drug price
may negatively inﬂuence drug listing, limiting the adop-
tion of new products. Reimbursement level assigned by
the Ministry of Health is considered an indicator of drug
beneﬁt evidence. CONCLUSIONS: Drug efﬁcacy is still
guiding product assessment process but cost-effectiveness
information is progressively gaining relevance. Decision
makers information on disease epidemiology and medical
need may be reinforced, allowing for better acceptance of
new effective product. Global treatment cost might be
considered in drug assessment instead of product price in
order to motivate manufacturers in producing robust and
credible economic information.
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OBJECTIVE: The Centers for Medicare and Medicaid
Services (CMS) computes clinical staff incident-to services
in physician ofﬁces under a zero work hour alternative
method. This study compares the results of CMS alter-
native method payment computations for indirect over-
head costs with the actual resource-based level of effort
for ofﬁce-based drug management costs as incurred 
in U.S. physicians’ ofﬁces. METHODS: Phase I: CMS
methods used for zero work hour practice expense rate-
setting were identiﬁed. Underlying assumptions were
examined and formal methodology evaluations were col-
lected. Phase II: On-site activity analyses were performed
in over 70 physicians’ ofﬁces located in 27 states. An
activity database was created from study data obtained
through direct observation and on-site interviews. Analy-
ses employing descriptive statistics identiﬁed activities,
tasks, and staff type involved in speciﬁc tasks, including
drug management. The activity analysis ﬁndings were
compared to the CMS reimbursement assumptions about
these activities. RESULTS: A database of CMS method-
ology explanations, visuals, and evaluations was created.
Activity analysis identiﬁed costs of labor and space to
order, track, receive, store and pay for the drug; drug
inventory carrying costs; net receivables carrying costs
and average bad debt cost. Study analyses illustrate that
current CMS practice expense payments do not ade-
quately recognize drug management costs in physicians’
ofﬁces. Study results revealed a statistically signiﬁcant dif-
ferential between actual and assumed use of administra-
tive labor for indirect overhead zero work pool tasks,
including those of drug management. CONCLUSIONS:
CMS zero work hour methodology to compute payments
for ofﬁce-based practice expense is deﬁcient as to drug
management costs. Payment for this component does not
align with actual practice occurring within the physicians’
ofﬁces. These ﬁndings will be of use to economists, cost
accountants, and policy makers interested in arriving 
at an equitable resource-based payment for drug 
management.
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OBJECTIVE: To examine consumers’ perspective of the
quality of prescription drug beneﬁt plans (Rx plan) using
a prescription-drug quality index. Additionally, con-
sumers’ satisfaction and perception of importance of Rx
plans were evaluated. METHODS: Consumers with pre-
scription drug beneﬁts were recruited from community
pharmacies and random-digit dialing (RDD) to partici-
pate in a telephone survey. The questionnaire was con-
structed from published literature and in-depth interviews
with six pharmacists, four consumers, and two employee
beneﬁt managers. RESULTS: Two hundred and one con-
sumers participated in a 20-minute telephone interview.
When asked to select optional health services over and
above hospital and medical services, 62.6% selected pre-
scription drugs services as most important. Using a 10-
point scale, with 10 as the highest score, the average
perceived quality rating of prescription drug beneﬁt plans
was 7.91 (2.0); the average rating for satisfaction with
the plan was 7.22 (2.3); and the average rating for impor-
tance of the plan was 9.15 (1.3). Few consumers (20%)
reported having plan-related problems when obtaining
prescription medications. The majority (87%) reported
having a copayment/coinsurance. The average prescrip-
tion drugs out-of-pocket payment was $560 (ranging
from $0–$7200) and the median was $200. Of the six
prescription-drug quality indicators, only two were found
